Specialty Pharmacy

Researchers pinpoint method to reverse cancer cell resistance to chemotherapy.

The growth rate for pharmacists is 14% by 2022.

How can stakeholders save money on the skyrocketing cost of specialty drugs?

Significant challenges remain due to lack of FDA action on existing biosimilar approval guidelines.

Actor and singer Charles Esten, whose daughter was diagnosed with leukemia when she was two and a half, shares the challenging and painful experiences of battling the disease.

The FDA today approved a new indication for ramucirumab for the treatment of metastatic non-small cell lung cancer.

Merck's anti"PD-1 therapy Keytruda has demonstrated an overall response rate of 18.5% among patients with PD-L1 positive, advanced triple-negative breast cancer, one of the most aggressive forms of breast cancer.

Targeted radiation may also be useful in treating other diseases.

Medication shows promising results in phase 3 study.

Actimab-A is an alpha radiolabeled antibody in development for newly diagnosed acute myeloid leukemia patients over the age of 60.

The role of pharmacists in HIV care across ambulatory care settings is expanding.

In healthy women, the cons of taking daily low-dose aspirin to prevent heart disease, cancer, and other serious illness outweigh the pros.

Raulo Frear, PharmD, general manager of OmedaRx, discusses effective strategies to ensure patients gain access to high cost specialty medications.

Cimetidine has clinically important benefits in improving colon cancer survival and preclinical evidence shows that this benefit may extend to other types of cancer.

Novo Nordisk announced that its phase 3 study of patients with hemophilia A, who had the highest annualized bleeding rates in its previous study, saw the biggest reduction in bleeding over the duration of treatment using turoctocog alfa.

Agent found to stop growth and spread of prostate cancer with a common chromosomal abnormality.

The FDA today approved of a new indication for Amgen's denosumab for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

Primary ADT associated with decreased survival in localized prostate cancer patients.

Onco360's industry-leading portfolio expanded to nearly 40 products.

According to a new study, a CCR5-blocking drug used to treat HIV may also be able to slow prostate cancer metastasis.

Valchlor has been approved for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.

Preliminary evidence indicates that new treatment is both safe and effective.

A compounding pharmacy in Newbern, Tennessee, and its co-owner have pleaded guilty to 1 misdemeanor criminal violation of the Federal Food, Drug, and Cosmetic Act.

Tablets treat HIV-1 infection in combination with other antiretroviral agents for pediatric patients.

Study suggests that HIV adaptations are evolving it into a weaker virus.

The FDA today approved ruxolitinib to treat patients with polycythemia vera, a chronic type of bone marrow disease.

Blincyto is the first approved drug that engages the body's T-cells to destroy leukemia cells.

Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses copay and reimbursement assistance programs.